Avacta Group Plc (AVCT)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013109)
◆英語タイトル:Avacta Group Plc (AVCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013109
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:41
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products which include optim and sensipod. It also develops UCB celltech, which is an analytical instrument. Avacta’s sensipod is an in-clinical blood testing system that delivers ELISA tests. The company offers intellectual property relating to an alternative to antibodies. It develops reagents and diagnostics which are used in affinity chromatography, protein to protein interactions, immunoassay and rapid diagnostic test applications, among others. It operates in Wetherby, Cambridge and London. Avacta is headquartered in Wetherby, the UK.

Avacta Group Plc (AVCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Avacta Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Avacta Group Plc, Medical Devices Deals, 2011 to YTD 2017 10
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Avacta Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 12
Avacta Enters into Agreement with Glythera 13
Avacta Enters Into Agreement With UbiQ Bio For Ubiquitin Affimers 14
Avacta Life Sciences Enters Into Co-Development Agreement With University of Liverpool 15
Avacta Enters Into Co-Marketing Agreement With Pall 16
Avacta Group Enters Into Distribution Agreement With Cold Spring Biotech 17
Licensing Agreements 18
Avacta Enters Into Licensing Agreement With Blueberry Therapeutics For Affimers 18
Equity Offering 19
Avacta Announces Private Placement Of Shares For US$17 Million 19
Avacta Group Announces Private Placement Of Shares For US$8.1 Million 21
Avacta Group Completes Private Placement Of US$3 Million 22
Asset Transactions 23
Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 23
Acquisition 24
Avacta Group Completes Acquisition Of Biotech Company Aptuscan For US$2.3 Million 24
Avacta Group Plc – Key Competitors 25
Avacta Group Plc – Key Employees 26
Avacta Group Plc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Financial Announcements 29
Aug 07, 2017: Avacta Group: Trading Update and Notice of Results 29
Apr 03, 2017: Avacta Group: Interim results for the period ended 31 January 2017 31
Oct 17, 2016: Avacta Group: Preliminary Results for the Year Ended 31 July 2016 32
Apr 25, 2016: Avacta Group: Interim Results for the Period Ended 31 January 2016 34
Corporate Communications 35
Jan 25, 2016: Avacta Appoints Philippe Cotrel as Chief Commercial Officer 35
Government and Public Interest 36
Jan 20, 2017: AGM business update and notice of results 36
Product News 37
Sep 22, 2016: Positive results from first preclinical in-vivo studies of Affimer therapeutics 37
Other Significant Developments 38
Aug 01, 2016: Avacta Group: Pre-close trading update 38
Apr 19, 2016: Affimer Therapeutic Platform Development Milestone Achieved 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Avacta Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Avacta Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Avacta Group Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Avacta Group Plc, Medical Devices Deals, 2011 to YTD 2017 10
Avacta Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 12
Avacta Enters into Agreement with Glythera 13
Avacta Enters Into Agreement With UbiQ Bio For Ubiquitin Affimers 14
Avacta Life Sciences Enters Into Co-Development Agreement With University of Liverpool 15
Avacta Enters Into Co-Marketing Agreement With Pall 16
Avacta Group Enters Into Distribution Agreement With Cold Spring Biotech 17
Avacta Enters Into Licensing Agreement With Blueberry Therapeutics For Affimers 18
Avacta Announces Private Placement Of Shares For US$17 Million 19
Avacta Group Announces Private Placement Of Shares For US$8.1 Million 21
Avacta Group Completes Private Placement Of US$3 Million 22
Unchained Labs Acquires Optim Technology from Avacta for USD5 Million 23
Avacta Group Completes Acquisition Of Biotech Company Aptuscan For US$2.3 Million 24
Avacta Group Plc, Key Competitors 25
Avacta Group Plc, Key Employees 26
Avacta Group Plc, Other Locations 27
Avacta Group Plc, Subsidiaries 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Avacta Group Plc (AVCT)-製薬・医療分野:企業M&A・提携分析(Avacta Group Plc (AVCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆